The Federal Circuit upheld the exclusion of a patent owner’s expert witness whose infringement opinion rested on a claim construction that materially differed from the district court’s adopted construction, resulting in summary judgment of noninfringement.
The Federal Circuit held that a patent owner’s disclaimer made for the first time during an IPR proceeding does not bind the PTAB in that same proceeding, preventing patentees from narrowing claim scope through argument alone to avoid invalidity.
The Federal Circuit held that a patent owner’s disclaimer made for the first time during an IPR proceeding does not bind the PTAB in that same proceeding, preventing patentees from narrowing claim scope through argument alone to avoid invalidity.
The Federal Circuit unanimously affirmed the district court’s holding that five patent claims covering ibrutinib (Imbruvica) — a breakthrough cancer drug — were not invalid for obviousness, lack of written description, or lack of enablement, underscoring appellate deference to trial court fact
The Federal Circuit held that the Patent Trial and Appeal Board may adopt claim constructions that differ from those entered by a district court in concurrent litigation, as the two proceedings are legally independent.
The Federal Circuit unanimously affirmed the district court’s holding that five patent claims covering ibrutinib (Imbruvica) — a breakthrough cancer drug — were not invalid for obviousness, lack of written description, or lack of enablement, underscoring appellate deference to trial court fact
The Federal Circuit held that the Patent Trial and Appeal Board may adopt claim constructions that differ from those entered by a district court in concurrent litigation, as the two proceedings are legally independent.
The Federal Circuit held that patent owners may amend claims during inter partes review to address issues beyond the specific grounds raised in the petition, provided the amendments do not enlarge claim scope or add new matter.
The Federal Circuit held that patent owners may amend claims during inter partes review to address issues beyond the specific grounds raised in the petition, provided the amendments do not enlarge claim scope or add new matter.
The Federal Circuit held that although an irrevocable patent license cannot be unilaterally revoked by the grantor, both parties may mutually agree to terminate it, and doing so restores the licensor’s standing to bring patent infringement suits against the former licensee.
The Federal Circuit held that although an irrevocable patent license cannot be unilaterally revoked by the grantor, both parties may mutually agree to terminate it, and doing so restores the licensor’s standing to bring patent infringement suits against the former licensee.
The Federal Circuit reversed a district court’s ruling that the claim term “Downloadable” was indefinite in Finjan’s computer virus detection patents, holding that the term’s plain meaning — an executable or interpretable application program — was sufficiently definite.
The Federal Circuit reversed a district court’s ruling that the claim term “Downloadable” was indefinite in Finjan’s computer virus detection patents, holding that the term’s plain meaning — an executable or interpretable application program — was sufficiently definite.
The Federal Circuit issued two precedential opinions vacating preliminary injunctions in hoverboard design patent cases, holding that courts must conduct product-by-product infringement analysis under the ordinary observer test and properly account for prior art when evaluating likelihood of success
The Federal Circuit issued two precedential opinions vacating preliminary injunctions in hoverboard design patent cases, holding that courts must conduct product-by-product infringement analysis under the ordinary observer test and properly account for prior art when evaluating likelihood of success
The Federal Circuit affirmed that IBM’s patents covering coordinated map-based and list-based selection of geographic data were directed to the abstract idea of organizing and displaying visual information, lacking an inventive concept sufficient for patent eligibility.
The Federal Circuit reversed an indefiniteness ruling against patents covering geometric meshing methods used in computer-aided design, holding that the district court applied an incorrect ‘unanswered questions’ test rather than the proper ‘reasonable certainty’ standard from
The Federal Circuit affirmed that IBM’s patents covering coordinated map-based and list-based selection of geographic data were directed to the abstract idea of organizing and displaying visual information, lacking an inventive concept sufficient for patent eligibility.
The Federal Circuit reversed an indefiniteness ruling against patents covering geometric meshing methods used in computer-aided design, holding that the district court applied an incorrect ‘unanswered questions’ test rather than the proper ‘reasonable certainty’ standard from
The Federal Circuit addressed trade secret and copyright claims arising from TA Instruments’ alleged misappropriation of Malvern Panalytical’s confidential algorithms and software for rheology instruments — affirming the district court’s rulings on preemption of state trade secret
The Federal Circuit addressed trade secret and copyright claims arising from TA Instruments’ alleged misappropriation of Malvern Panalytical’s confidential algorithms and software for rheology instruments — affirming the district court’s rulings on preemption of state trade secret
The Federal Circuit reversed dismissal of a peer-to-peer video delivery network patent under § 101, holding that the complaint plausibly alleged the claims represented a specific technical improvement over prior content distribution networks.
The Federal Circuit reversed dismissal of a peer-to-peer video delivery network patent under § 101, holding that the complaint plausibly alleged the claims represented a specific technical improvement over prior content distribution networks.
The Federal Circuit affirmed infringement of Corcept Therapeutics’ method-of-treatment patents covering combination therapy using mifepristone with a strong CYP3A inhibitor — finding that Teva’s ANDA label induced infringement and rejecting Teva’s challenge to the skinny label carv